Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC)

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Proteolysis-targeting chimeras (PROTACs) leverage the ubiquitin-proteasome system for targeted protein degradation, showing therapeutic promise.
• Current PROTAC development faces limitations in E3 ligase and degradation signal sequence adaptation.

Purpose of the Study:

• To develop novel PROTACs using simple amino acids as ligands for E3 ligase recruitment.
• To investigate the efficacy of these amino acid-based PROTACs (AATacs) against oncogenic drivers in non-small cell lung cancer (NSCLC).

Main Methods:

• Utilized Gly, Pro, and Lys as ligands to recruit CRL2ZYG11B/ZER1, GID4, and UBRs E3 ligases, respectively.
• Designed and tested AATacs targeting EML4-ALK and mutant EGFR in NSCLC cell lines.
• Assessed protein reduction, proliferation, cell cycle arrest, and apoptosis.

Main Results:

• AATacs successfully degraded EML4-ALK and mutant EGFR.
• Protein reduction levels were fine-tunable by varying degradation signals.
• AATacs inhibited NSCLC cell proliferation, induced cell cycle arrest, and promoted apoptosis in vitro.
• AATacs demonstrated small size and interchangeability with varying degradation efficiencies.

Conclusions:

• Amino acid-based PROTACs (AATacs) represent a novel and versatile class of targeted protein degraders.
• This approach expands the available E3 ligase repertoire for PROTAC applications.
• AATacs offer a promising therapeutic strategy for NSCLC by degrading key oncogenic drivers.